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Flow chart of molecular imaging in drug development 
Elisabeth G.E. de Vries et al. Cancer Discovery 2011;1:25-
28
Can we say the same for therapeutic radiopharmaceuticals?
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< 5% of in vitro targets allow development of an in vivo probe? 
– how many potential radiopfarmaceuticals ?  and how many for for therapy ?
• High TARGET activity / concentration
• Affinity and specificity 
• Absence of biological barriers (i.e. endothelium, blood brain barrier, ...) 
• Stable labeling of compound
• Low BACKGROUND activity
– Non-specific accumulation, 
– Circulating or interstitial activity 
– Renal or hepatic elimination
• Signal amplification 
– Cell trapping 
– Enzymatic conversion 
– "Reporter" molecules: fluorescence, radiation, magnetic
Development of in vivo probes / potential radiopfarmaceuticals for therapy
Toxicology 
What are the toxicity target organs? Are toxic effects reversible? 
Is the drug mutagenic, carcinogenic or toxic to reproduction? 
Are there adverse effects on cardiovascular, neurological or 
respiratory function? 
Are there any toxic metabolites? 
Are there any toxic impurities in production batches for clinical use? 
Toxicokinetics 
How are toxic effects related to dose and systemic concentrations? 
Which enzymes are involved in the drug’s metabolism? 
What are the metabolites and what is their activity on- and off-target? 
Are there species differences in absorption, distribution, metabolism, 
and excretion?
Preclinical questions 
What information is to be included in the Investigator's Brochure? 
What (additional) safety endpoints need to be monitored in human 
trials? 
What is the proposed human starting dose and its margin of safety? 
What is the proposed human dose escalation step size? 
Preclinical safety testing of diagnostic and therapeutic radiopharmaceuticals -
regulatory requirements 
Radiopharmaceuticals  - regulation and leglisation
Investigational Medicinal Products (IMPs)
The Clinical Trials Directive 2001/20/EC, Article 2 (d), provides the following definition for an Investigational 
Medicinal Product (IMP): "a pharmaceutical form of an active substance or placebo being tested or used as a 
reference in a clinical trial, including products already with a marketing authorization but used or assembled 
(formulated or packaged) in a way different from the authorised form, or when used for an unauthorised indication, or 
when used to gain further information about the authorised form." 
Radiopharmaceuticals which may be classified as IMPs include radiolabelling kits, 
radionuclide generators and radionuclide precursors.
(http://ec.europa.eu/health/files/pharmacos/docs/doc2006/07_2006/def_imp_2006_07_27_en.pdf)
EU Investigational Medicinal Product (IMP) Safety documentation requirements for 
radiopharmaceuticals [radionuclide generators, kits, radionuclide precursor radiopharmaceuticals 
and industrially prepared radiopharmaceuticals] : 
Standard requirements for medicinal products [= ICH M3(R2) for preclinical safety] 
Radiation dosimetry - Organ/tissue exposure to radiation; - Absorbed radiation dose 
estimates for a given route of administration according to a specified, internationally 
recognised system.
“Medicinal products” are defined by Directive 2001/83/EC as "…prepared industrially 
or manufactured by a method involving an industrial process…". 
Therapeutic Radiopharmaceuticals Single-dose toxicity: These studies may give some 
indication of the likely effects of acute overdosage in man and may be useful for the design 
of toxicity studies requiring repeated dosing in the relevant animal species 
Reproductive function and foetal toxicity: Studies may be required in certain cases, 
especially if the radiopharmaceutical is intended for repeated use in women of child-bearing 
potential. Otherwise the study on reproductive function may justifiably be limited to 
ascertaining the effect on fertility. 
Mutagenic potential: Characterization of the mutagenic potential of the non-radioactive 
equivalent of the product; may be limited to screening for gene and chromosome mutations. 
Carcinogenic potential: An evaluation of any carcinogenic potential of the substances 
involved must be presented. If no carcinogenicity tests are performed, this must be clearly 
indicated. 
There are two IND categories:
• Commercial
• Research (non-commercial)
The IND application must contain information in three broad areas:
• Animal Pharmacology and Toxicology Studies - Preclinical data to permit an assessment as to whether the 
product is reasonably safe for initial testing in humans. Also included are any previous experience with the drug in humans 
(often foreign use).
• Manufacturing Information - Information pertaining to the composition, manufacturer, stability, and controls used 
for manufacturing the drug substance and the drug product. This information is assessed to ensure that the company can 
adequately produce and supply consistent batches of the drug.
• Clinical Protocols and Investigator Information - Detailed protocols for proposed clinical studies to assess 
whether the initial-phase trials will expose subjects to unnecessary risks. Also, information on the qualifications of clinical
investigators--professionals (generally physicians) who oversee the administration of the experimental compound--to assess 
whether they are qualified to fulfill their clinical trial duties. Finally, commitments to obtain informed consent from the 
research subjects, to obtain review of the study by an institutional review board (IRB), and to adhere to the investigational
new drug regulations.
https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/investigationalnewdrugindapplication/defa
ult.htm
Investigational New Drug (IND) Application - FDA
Oct 5, 2017
A physician may decide to request use of an investigational antiviral product through a single-patient 
Emergency Investigational New Drug (EIND) application if:
• the physician considers the product may be urgently needed for the patient’s serious or life-threatening condition;
• no satisfactory alternative therapy is available; and
• the patient cannot receive the product through any existing clinical trials or expanded access protocols
Emergency Investigational New Drug (EIND)
Biodistribution A physiological distribution test is prescribed, if necessary, for certain 
radiopharmaceutical preparations. 
The distribution pattern of radioactivity observed in specified organs, tissues or other body 
compartments of an appropriate animal species (usually rats or mice) can be a reliable indication of 
the expected distribution in humans and thus of the suitability of the intended purpose. 
The preparation meets the requirements of the test if the distribution of radioactivity in at least two of 
the three animals complies with the criteria specified in the monograph. 

Schematic Representation of a Drug for Imaging and Targeted Therapy
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Target and molecular addresses
Radionuclide Half-life Mode of decay Energy (keV)
THERAPY
90Y 64.1 h β- 2282.0
131I 8.0 d β-, g 970.8
153Sm 46.3 h β-, g 808.4
89Sr 50.5 d β- 1496.6
177Lu 6.7 d β-, g 498.2
188/186Re 16.9 h β-, g 2120.4
Radionuclide Half-life Mode of decay Energy (keV)
THERAPY
211At 7.2 h α 6790
67Cu 61.9 h β-, g 577
212/213Bi 60/46 min α 8320
225Ac 10.0 d α 5750
223Ra 11.43 d α 5780
Theranostics
Nuclear probes
PET/SPECT for imaging
Particle emitters for targeted radionuclide therapy
Optical probes
Photodynamic therapy
MRI probes
Gd-complexes
Gd based neutron 
capture therapy
Imaging
Development of multimodality probes for theranostic aplications
Theranostics: combination of diagnosis and therapy
Personalized medicine/tailored medicine/
Matching the right drug for the right patient
Matched b+/b- pairs 
• 64Cu/67Cu
• 86Y/90Y
• 44Sc/47Sc
• 124I/123/131I
The „twin” isotope of the same element can be used for diagnostic 
imaging or therapy follow up,  while the other is used for therapy 
using the same carrier molecules. 
Matched Radionuclide Pairs for Imaging and Therapy (edited by A. Bockish) 
Eur J Nucl Med Mol Imaging, Vol 38, Suppl 1, June 2011 
Chelators
used to bind the a radioisotope molecule 
so that  when injected into a patient,  the targeting molecule can 
be delivered  without any radioisotope loss
Wadas TJ et al. Chem Rev 2010;110(5):2858-2902
The “right” cells - the good model
In vitro  binding study /affinity, immunoreactivity, specific binding
BASIC / PRECLINICAL RESEARCH
- Study of mechanisms of disease development and progression 
- Detection and activity of receptors and pathways Pharmacokinetics / 
pharmacodynamics of target drugs
In vivo study in Balb/c mice or Wistar rat
Injection of
Radioisotope/ ligand 4 h24h
48h
72h
Biodistribution
In vivo studies in tumor bearing mice
Tumor cell culture
2–3 weeks
Injection of 
Radiolabeled ligand
Mice subcutaneously 
xenografted with 2 mln cells
Biodistribution
4 h
24h
48h
72h
Animal scanner
or Optical Imaging
● The shift to applied research
● Medicalization of research
● Technical development
● Linkage 
Animal model in preclinical studies
Animals have long been used as subject in laboratory 
experiments,  as they were considered viable alternatives 
of the use of humans.
Of Mice and Humans: Are They the Same?
Challenge – to identify an animal model that is comparable to humans
Problems:
- The design (small/larger groups) of animal studies, the 
experimental execution, the evaluation of the data are under 
purview of one, no masked person – elucidated certain weakness, 
lack of masking and limit the translation value to human application.
- Choice of the animal – often young, rarely comorbidities, not 
exposed to the full range interventions that human often received.
- To select positive animal data, but to ignore equally valid but 
negative work when planning clinical trials
- Reporting experimental design
- Masking and randomization
- Comparison the treatment effects
- Use systematic review of human and clinical studies
Everyone: 
Keep Good Records!!
Animal handling and Anesthesia
Why ?
- decrease motion artifact 
- decrease pain and stress?
Indications for awake imaging
- avoid influence of anesthesia on:  blood flow, metabolism, 
neural-vascular coupling
- elucidate disease pathophysiology
- drug/radiopharmaceutical development
- mimic the human state
blood 14 MAY 2009 I VOLUME 113, NUMBER 20
David M. Goldenberg
Some like it hot: 
Radioimmunotherapy
From our experience
Bivalent hapten-bearing peptides designed for 
iodine-131 pretargeted radioimmunotherapy
E Janevik-Ivanovska, E Gautherot, M Hillairet de 
Boisferon, M Cohen, ...
Bioconjugate chemistry 8 (4), 526-533
Radiolabeled bivalent haptens for tumor 
immunodetection and radioimmunotherapy
A Gruaz-Guyon, E Janevik-Ivanovska, O Raguin, 
C De Labriolle-Vaylet, ...
The Quarterly Journal of Nuclear Medicine and 
Molecular Imaging 45 (2), 201
OUR EXPERIENCE:
ESTABLISHMENT AND STANDARDIZATION OF A TECHNOLOGY FOR THE PRODUCTION OF READY-TO-
USE COLD KIT FORMULATIONS FOR LABELLING OF CONJUGATED ANTIBODIES WITH Lu-177
Bifunctional chelating agents
p-SCN-Bn-DOTA
Para isothiocyanatobenzyl 
derivate - DOTA
p-SCN-Bn-DTPA
Para isothiocyanatobenzyl derivate of DTPA
1B4M-DTPA
2-(4-isothiocyanatobenzyl)-6-methyldiethylene - DTPA
Rituximab:BFCAs
1:20
Rituximab:BFCAs
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Part of the IAEA’s Coordinated Research Project (CRP)
kDa
SDS-PAGE electrophoresis of immunoconjugate
Rituximab-DTPA-SCN
Rituximab -DОТA-SCN Rituximab -DTPA-1В4М
Scanning electronic microscopy of freeze drying Rituximab conjugate 2 µm 
p-SCN-Bn-DOTA
1B4M-DTPA  p-SCN-Bn-DTPA
Schematic process of conjugation and non-radioactive labeling of three BFCA-rituximab 
MALDI-TOF results for three BFCA-rituximab 
(1: p-SCN-Bn-DOTA; 2: p- SCN-Bn-DTPA and 3: 1B4M-DTPA) Raman and ATR-IR spectra of rituximab -conjugates
31
Animal studies with not radioactive Lu/Y-labeled 
imunoconjugate of Rituximab for determination of 
normal tissue toxicity
Group
RBC WBC PLT
Normal values
7,21 – 8,45
х1012/L
7,2 – 12,6
x109/L
250 – 1200
x109/L
Average value from group I (Lu-
DOTA-Rituximab)
3,40 7,8 1496,5
Average value from group II (Lu-
DTPA-Rituximab )
3,05 8,06 558
Average value from group III 
(Lu-1B4M-DTPA-Rituximab)
3,69 9,375 984
Average value from group IV (Y-
DOTA-Rituximab)
2,83 10,74 770,66
Average value from group V (Y-
DTPA-Rituximab)
3,288 9,66 1802
Average value from group VI (Y-
1B4M-DTPA-Rituximab)
3,575 9,10 1332,5
* Results are average from the values after 3 weeks aplication
Blood sample
(6 groups х 5 animal)
Rituximab conjugateт
(3 weeks)
Blood sample 
(every week)
Blood sample + liver an spleen sample for 
immunochemistry (week 4)
Animal studies with not radioactive Lu/Y-
labeled imunoconjugate of Rituximab for 
determination of normal tissue toxicity after 
4 weeks from the last treatment 
Group
RBC WBC PLT
Нормални вредности
7,21 – 8,45
х1012/L
7,2 – 12,6
x109/L
250 – 1200
x109/L
Average value from group I (Lu-
DOTA-Rituximab)
6,90 6,50 652
Average value from group II (Lu-
DTPA-Rituximab )
5,39 1,80 71
Average value from group III 
(Lu-1B4M-DTPA-Rituximab)
7,05 3,80 963
Average value from group IV (Y-
DOTA-Rituximab)
4,21 0,70 30
Average value from group V (Y-
DTPA-Rituximab)
6,80 7,10 824
Average value from group VI (Y-
1B4M-DTPA-Rituximab)
6,98 3,30 1075

Specific binding over total applied radioactivity as a function of cell concentration in: 
a) 177Lu-DOTA-rituximab and                            b) 177Lu-DTPA-rituximab. 
Animal studies - Double xenografts in Nude mice 
specific vs non-specific uptake
Patient – Dog with B limphoma
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